AstraZeneca Pharma Share Price: The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple ...

The Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of ...

Sun Pharma has partnered up with Bayer to market Finerenone, a drug for chronic kidney disease, in India. Bayer grants non-exclusive rights...

Bicara, founded in 2020 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company currently developing dual-action b...

Researchers from various countries, including an alumnus of Allahabad University, have discovered a compound derived from tobacco leaves th...

The treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso.

You may be losing kidney functions for many years without significant symptoms. People often get to know about their condition only when th...

The AI tool was also able to determine whether abnormal versions of 6 genes linked to lung cancer were present in cells.

Britain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.

Called ALZUMAb, it took 10 years in the making and "is recognition of innovation done by research and development wing of Biocon," said Kir...

Biotechnology major Biocon today said it is looking for partners to develop and market its novel biologic drug Itolizumab

The company had received marketing authorisation for Itolizumab from the Drugs Controller General of India (DCGI) in January, 2013.

Biotech major, Biocon, has decided to split its cardio-diabetes group by launching a stand alone cardiology division.

The deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.

Bangalore-based Biocon has posted a consolidated net profit of Rs 61 crore for the fourth quarter ended March 31, 2007, up 27% from Rs 48 c...

Leading biotech company, Biocon Limited on Monday said it expects to launch a new anti-arthritis drug in the next 3-4 years in the market, ...

Biotechnology behemoth Biocon has launched BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumours of epitheli...